Literature DB >> 6172392

Epstein-Barr virus strain- and group-specific antigenic determinants detected by monoclonal antibodies.

N Mueller-Lantzsch, B Georg-Fries, H Herbst, H zur Hausen, D G Braun.   

Abstract

In order to differentiate Epstein-Barr virus (EBV) strains by serological markers we prepared hybridomas producing monoclonal antibodies against polypeptides of the QIMR-WIL EBV strain. These monoclonal antibodies were screened by indirect immunofluorescence techniques. Immunoprecipitation using EBV-positive monoclonal antibodies and the protein A method, of 125I-labelled polypeptides from purified QIMR-WIL EBV particles, revealed that a series of monoclonal antibodies against the four main surface and envelope polypeptides precipitating p340, p340/p240, p140, and p80 were obtained. When 125I-labelled polypeptides from purified P3HR-1 and B95-8 EBV particles were immunoprecipitated, it could be demonstrated that several anti-p340 (QIMR-WIL) antibodies recognized strain-specific antigenic determinants, while anti-p340/p240 (QIMR-WIL) as well as anti-p140 (QIMR-WIL) antibody clones reacted with antigenic sites which are in common wither among B95-8 or in addition to P3HR-1 polypeptides. Thus, monoclonal antibodies now provide a serological basis for EBV typing.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6172392     DOI: 10.1002/ijc.2910280311

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus.

Authors:  B Vroman; J Luka; M Rodriguez; G R Pearson
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

2.  Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.

Authors:  T Sairenji; G Bertoni; M M Medveczky; P G Medveczky; Q V Nguyen; R E Humphreys
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

Review 3.  Monoclonal antibodies against microorganisms.

Authors:  R A Polin
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 4.  Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine.

Authors:  M A Epstein; A J Morgan
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

5.  Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus.

Authors:  C M Edson; D A Thorley-Lawson
Journal:  J Virol       Date:  1983-05       Impact factor: 5.103

6.  Modification of Epstein-Barr virus replication by tunicamycin.

Authors:  L M Hutt-Fletcher; N Balachandran; P A LeBlanc
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

7.  Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.

Authors:  J R North; A J Morgan; J L Thompson; M A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  Epstein-Barr virus induced proteins V: comparison of EBV-specific polypeptides from different virus strains.

Authors:  B Georg-Fries; N Mueller-Lantzsch
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

9.  Monoclonal antibody specific for capsid antigen of Epstein-Barr virus.

Authors:  K Takada; S Fujiwara; S Yano; T Osato
Journal:  Med Microbiol Immunol       Date:  1983       Impact factor: 3.402

10.  Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen.

Authors:  T Sairenji; P S Reisert; R C Spiro; T Connolly; R E Humphreys
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.